New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
14:51 EDTMDXGMiMedx addressed reimbursement fears on call, says Craig-Hallum
Craig-Hallum said MiMedx management outlined reimbursement scenarios for when the company no longer has pass-through status, calming the fears of some investors. Craig-Hallum also noted that the company raised the lower-end of its FY14 revenue guidance to $95M from $90M and that management said its meeting with the FDA about its micronized injectable products was both "productive and helpful." The firm reiterates its Buy rating and $10 price target on MiMedx.
News For MDXG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
07:45 EDTMDXGMiMedx upside seen in new markets, says Canaccord
Subscribe for More Information
February 26, 2015
07:36 EDTMDXGMiMedx backs FY15 revenue view $175M-$190M, consensus $183.61M
Subscribe for More Information
07:36 EDTMDXGMiMedx backs Q1 revenue view $40M-$41M, consensus $40.54M
Subscribe for More Information
07:34 EDTMDXGMiMedx reports Q4 EPS 3c, consensus 3c
Subscribe for More Information
February 20, 2015
10:01 EDTMDXGOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:17 EDTMDXGMiMedx upgraded to Strong Buy with $13 target at Needham
Needham upgraded MiMedx to Strong Buy from Buy saying it has renewed confidence the company can exceed consensus 2015 estimates after meeting with management. The firm has a $13 price target for shares.
06:45 EDTMDXGMiMedx upgraded to Strong Buy from Buy at Needham
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use